Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia by Mooberry, et al.
Procoagulant Microparticles Promote Coagulation in a Factor XI-
Dependent Manner in Human Endotoxemia
M. J. Mooberry*, R. Bradford†, E. L. Hobl‡, F. C. Lin§, B. Jilma‡, and N. S. Key*,†
*Department of Medicine, University of North Carolina, Chapel Hill, NC
†McAllister Heart Institute, University of North Carolina, Chapel Hill, NC
‡Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
§Department of Biostatistics, University of North Carolina, Chapel Hill, NC
Summary
Background—Human endotoxemia is characterized by acute inflammation and activation of 
coagulation, as well as increased numbers of circulating microparticles (MPs). Whether these MPs 
directly promote coagulation and through which pathway their actions are mediated, however, has 
not been fully explored.
Objectives—In this study, we aimed to further characterize endotoxin-induced MPs and their 
procoagulant properties using several approaches.
Methods—Enumeration and characterization of MPs were performed using a new generation 
flow cytometer. Relative contributions of the extrinsic and intrinsic pathways in MP-mediated 
procoagulant activity were assessed using plasmas deficient in FVII or FXI or with blocking 
antibodies to tissue factor (TF) or FXIa.
Results—Total MPs and platelet MPs were significantly elevated in plasma at 6 hours after 
infusion of endotoxin in healthy human subjects. MPs isolated from plasma following endotoxin 
infusion also demonstrated increased TF activity in a re-constituted buffer system. When added to 
re-calcified platelet poor plasma, these MPs also promoted coagulation, as judged by a decreased 
clotting time with shortening of the lag time and time to peak thrombin using calibrated automated 
thrombography (CAT). However, the use of FVII deficient plasma or blocking antibody to TF did 
not inhibit these procoagulant effects. In contrast, plasma clotting time was prolonged in FXI 
deficient plasma, and a blocking antibody to FXIa inhibited all MP-mediated parameters in the 
CAT assay.
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Conclusions—The initiation of coagulation by cellular TF in endotoxemia is in contrast to (and 
presumably complemented by) the intrinsic pathway-mediated procoagulant effects of circulating 
MPs.
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Introduction
The human endotoxemia model, in which purified lipopolysaccharide (LPS) from 
Escherichia coli is infused into healthy individuals is a model of acute systemic 
inflammation, which partially mimics the initial inflammatory response in the early stages of 
sepsis and other acute inflammatory disorders [1, 2]. Given the close association and 
interplay between inflammation and coagulation, this model has also been very informative 
in the study of acute activation of coagulation [3, 4].
Microparticles (MPs) are membrane vesicles (0.1 to 1 μm) released from cells upon 
activation or apoptosis. The hemostatic and/or thrombotic function(s) of MPs may be related 
to the presence of phosphatidylserine (PS) on the outer membrane leaflet, as well as the 
presence of tissue factor (TF) on some MPs [5]. PS exposure allows for docking of calcium-
dependent coagulation enzymatic complexes and provides a catalytic surface for the tenase 
and/or prothrombinase complexes that promote thrombin generation [6]. TF, the 
transmembrane receptor for Factor VII/VIIa, is believed to be the principal initiator of 
coagulation in vivo [7]. Blood-borne TF resides primarily in the cellular fraction, with 
monocytes being the dominant source. In certain situations, TF may also be expressed by 
other cells, such as endothelial cells and platelets, although this is actively debated [8, 9]. 
Although MP-associated TF represents only a small fraction of TF in blood, it has been 
shown to contribute to thrombus formation in vivo in animal models [10].
Prior investigations into the activation of coagulation in endotoxemia have provided 
evidence for both intrinsic and extrinsic pathway participation. DeLa Cadena and colleagues 
demonstrated activation of the contact pathway in a human model of endotoxemia by 
showing decreased FXI functional activity, decreased prekallikrein (PK) antigen and activity, 
and increased levels of α2-macroglobulin-kallikrein complexes after endotoxin 
administration [11]. Similar findings were seen with ex vivo endotoxin treatment of whole 
blood in a time- and dose-dependent manner [12]. Animal models of endotoxemia have also 
provided evidence for contact pathway activation, with decreases in FXII, and in PK and 
high molecular weight kininogen, in rabbits [13], and dogs [14], respectively. In other 
studies, however, evidence for activation of the contact pathway has not been confirmed [15, 
16].
Conversely, there is ample evidence for a role of the extrinsic pathway in the activation of 
coagulation in endotoxemia. Increased intracellular and surface expression of TF on 
circulating monocytes is detectable after ex vivo LPS stimulation [17]. Similarly, total whole 
blood TF mRNA is increased in human endotoxemia [18, 19], in addition to MP-TF and 
whole blood TF activity [20]. Perhaps most convincingly, it has been shown that inhibition 
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of the extrinsic pathway, using either anti-TF antibodies [21–23], active site-inactivated 
FVIIa [24], tissue factor pathway inhibitor (TFPI) [25], or genetically altered animals with 
either low TF [26] or FVII levels [27], have attenuated coagulopathy and improved survival 
in animal models of endotoxemia and sepsis.
Circulating MPs, including those bearing tissue factor (TF+-MPs), have been demonstrated 
to increase after endotoxin administration [20, 28] and are presumed to contribute to 
activation of coagulation. However, whether MPs contribute directly to coagulation 
activation in endotoxemia, and whether their effects are mediated preferentially through one 
of the pathways has not been well studied. Therefore, in this study, we used a new 
generation flow cytometer to characterize the circulating MP profile by number and 
phenotype. MP-dependent procoagulant activity was then interrogated to determine the 
relative contributions of the intrinsic and extrinsic pathways. Together these data help to 
further characterize the cellular origin of MPs and their role in the activation of coagulation 
in human endotoxemia.
Materials and Methods
Study Design and Sample Processing
The study was approved by the Ethics Committee at the Medical University of Vienna. 
Seventeen healthy subjects were enrolled in a trial using an established model of low grade 
endotoxemia [29]; subjects were infused with 2 ng/kg LPS (CCRE lot kindly provided by 
the NIH), with blood samples obtained at 4 time points (baseline [BL], 3, 6, and 24 hours 
post-LPS infusion). Samples from the 24-hour time point were available in only12 subjects.
Blood was collected into 3.8% citrated tubes (Vacutainer®; Becton Dickinson), with the first 
2–3 mLs discarded. Platelet free plasma (PFP) was obtained immediately by two sequential 
centrifugations, each at 2,500g for 15 minutes, as per the International Society on 
Thrombosis and Haemostasis pre-analytical protocol for MP analysis by flow cytometry 
[30], and stored at −80°C until analysis.
Materials
TAT ELISA kit (Enzygnost® TAT micro kit) and human recombinant relipidated TF 
(Innovin®) were purchased from Siemens (Muenchen, Germany). Zymuphen MP-activity 
kit was from Aniara (West Chester, OH, USA). Control monoclonal antibody (mouse IgG) 
was from Sigma-Aldrich (St. Louis, MO, USA). FX and FVIIa were from Enzyme Research 
Laboratories (South Bend, IN, USA). FXa chromogenic substrate (Pefachrome® FXa8595) 
was from Pentapharm (Basel, Switzerland). Mouse anti-human TF monoclonal antibody 
(HTF-1) was provided by Dr. Ronald Bach (VA Medical Center; Minneapolis, MN, USA). 
AnnexinV-FITC, APC-labeled anti-CD41a, and FITC-labeled anti-CD31 were from BD 
Pharmingen (San Jose, CA, USA). PE-labeled anti-human CD235a was from Biolegend 
(San Diego, CA, USA). PE-labeled anti-CD14 was from eBioscience (San Diego, CA, 
USA). Gigamix beads were a gift from Philippe Poncelet (Biocytex; Marseille, France). 
CytoCount™ beads were from Dako (Carpinteria, CA, USA). FVII-deficient and FXI-
deficient plasmas were from diaPharma (West Chester, OH, USA). Lipid vesicles were from 
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Avanti Polar Lipids (Alabaster, AL, USA), and large unilamellar vesicles containing 15% 
phosphatidylserine (PS) were prepared by extrusion as previously described [31, 32]. 
Thrombin fluorogenic substrate (Z-Gly-Gly-Arg-AMC) and calibrator (α2-macroglobulin/
thrombin) were from Diagnostica Stago (Parsippany, NJ, USA). Mouse anti-human Factor 
XIa antibody (aXI) and corn trypsin inhibitor (CTI) were from Haematologic Technologies, 
Inc. (Essex Junction, VT, USA).
MP Enumeration and Characterization by Flow Cytometry
PFP aliquots (30 μL) were stained with different combinations of the following markers/
antibodies: 10 μL AnnexinV-FITC mixed 1:1 with Annexin binding buffer (10 mM HEPES, 
140 mM NaCl, 2.5 mM CaCl2), 10 μL APC-labeled anti-CD41a, 10 μL PE-labeled anti-
CD14, 10 μL FITC-labeled anti-CD31, and 2 μL PE-labeled anti-CD235a. All markers/
antibodies were centrifuged at 20,000g x 20 min prior to use. Platelet-derived MP (PMP), 
monocyte-derived MP (MMP), endothelial-derived MP (EMP), and red cell-derived MP 
(RMP) subsets were identified (Figure 1C–F). Total MPs (TMPs) were defined as all 
AnnexinV+ events falling within the MP gate. MP size gate was set between 200–1,000 nm 
utilizing Gigamix® beads. Calcium-free samples and single-stained MP-free plasma 
(supernatant from normal, healthy donor PFP centrifuged at 100,000g x 60 minutes) were 
used as negative controls. Stained samples were incubated in the dark for 20 minutes and 
then diluted with Annexin binding buffer (500 μL) prior to analysis. All buffers were 0.1 μm 
filtered. CytoCount® beads (30 μL) were added to each sample immediately prior to 
analysis. MP concentration was calculated as follows: (MP counted x concentration of 
beads)/number of beads counted. All samples were analyzed on a Stratedigm S1000Ex 
(Stratedigm; San Jose, CA, USA) new generation flow cytometer equipped with a forward 
scatter photomultiplier tube using a side scatter trigger and with 0.1 μm filtered sheath fluid. 
Event rates were maintained at < 8,000 events/second to minimize coincident events, with 
more highly concentrated samples requiring further dilution prior to enumeration.
Microparticle Tissue Factor (MP-TF) Activity in Isolated MPs
MP-TF activity in isolated MPs was measured using a two stage chromogenic assay as 
previously described [33]. MP-TF activity was run on a random subset of patients (BL, 3 hr, 
6 hr = 5 subjects; BL, 3 hr, 6 hr, 24 hr = 8 subjects). Since previous studies have also shown 
a reproducible peak in plasma TAT complexes at 3 hours [34], TATs were only measured at 
this time point.
MP Procoagulant Activity
MP prothrombinase activity was assayed using the Zymuphen™ MP-Activity kit, according 
to manufacturer’s instructions. Notably, the functional part of this assay is not performed in 
a plasma milieu. Therefore, using a more physiologically relevant endpoint of clot 
formation, MP procoagulant activity was also measured in a plasma milieu using an in-
house clotting assay (re-calcification time). Briefly, MPs from baseline and 3 hour time 
points were isolated from subject plasma by high-speed centrifugation (20,000 g x 30 min) 
and re-suspended in an equal volume of HBSA. Re-suspended MPs (50 μL) were incubated 
with various factor-deficient and control plasmas (50 μL) at 37°C for 2 minutes. After re-
calcification with 25 mM CaCl2 (50 μL), clotting times were measured using a STart® 4 
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Hemostasis Analyzer (Diagnostica Stago; Parsippany, NJ, USA). HBSA alone incubated 
with normal control plasma was used as a negative control. Plasmas used included: 1) 
normal, pooled PFP from citrated whole blood (prepared identically to endotoxemia samples 
as described in Study Design section); 2) FVII-deficient plasma; and 3) FXI-deficient 
plasma. Exogenous phospholipid (4 μM final) was added to all plasma preparations prior to 
incubation with MPs.
Calibrated Automated Thrombogram (CAT)
MP contribution to thrombin generation in plasma was measured using CAT as previously 
described [35], with minor modifications. Briefly, MPs were isolated from the plasma of 
eight additional subjects using high-speed centrifugation (20,000 g x 30 min). The MP pellet 
was then re-suspended in an equal volume of MP-depleted normal pooled plasma (NPP). 
NPP was prepared from multi-donor whole blood collected in citrate and CTI (18 μg/mL) 
and initially centrifuged to yield platelet free plasma, with a second high speed 
centrifugation (20,000 g x 20 min) to remove residual MPs. NPP was collected in citrate 
plus CTI to prevent ex vivo contact pathway activation in the substrate plasma that could 
serve as a stimulus for thrombin generation [36]. Next, 80 μL of re-suspended MPs were 
incubated with or without blocking antibodies to TF or FXIa, respectively (HTF-1 or anti-
FXIa; 40 μg/mL final), for 10 minutes. MP reagent supplied by the manufacturer (20 μL), 
and consisting of phospholipid (4 μM final), was then added and allowed to incubate for 10 
minutes. Finally, thrombin generation was initiated by dispensing fluorogenic substrate in 
CaCl2 (416 μM and 16 mM final, respectively), calibrated against wells containing α2-
macroglobulin/thrombin and plasma, and analyzed with Thrombinoscope software v3.0.0.29 
(Thrombinoscope BV, Maastricht, the Netherlands). To ensure the absence of ex-vivo 
generated FXIa bound to MPs that could influence thrombin generation, PFP from one 
subject at the 3 hour time point and from whole blood treated ex-vivo with LPS was treated 
with PPACK 1 μM for 10 minutes prior to MP isolation. MPs were then washed once before 
CAT analysis. Additional aliquots of each PFP sample were also run in parallel without 
PPACK treatment. Parallel samples of PFP from ex-vivo LPS treated whole blood were also 
assessed for residual FXIa activity using a chromogenic substrate for FXIa with either no 
treatment, a single wash, or PPACK treatment followed by a single wash.
Statistics
We report descriptive statistics, including mean ± standard deviation (SD) or median 
[interquartile range (IQR)] as indicated, depending upon the distribution of the data 
analyzed. Normality was assessed using the Shapiro-Wilk normality test. Changes over time 
in MP-TF activity, clotting times and thrombin generation parameters (peak thrombin, time 
to peak thrombin, lag time, and endogenous thrombin potential [ETP]) were analyzed using 
one-way repeated measurements ANOVA with Tukey’s multiple comparisons test. For ETP 
analysis, a value of zero was assigned to all samples that had such low levels of thrombin 
generation that area under the curve could not be calculated. Zymuphen MP Activity and 
MP flow cytometry data were analyzed using the Friedman test with Dunn’s multiple 
comparisons test. TAT complexes were analyzed using the paired Student’s t-test. Pearson 
and Spearman correlation coefficients were used according to the distribution of data being 
analyzed. P values < 0.05 were considered significant.
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Results
Total and Platelet MP Numbers in Plasma are Increased in Endotoxemia
Utilizing a new generation flow cytometer, we can reliably resolve polystyrene particles as 
small as 200 nm by scatter detection alone (Figure 1A,B). In endotoxemia plasmas, 
significant increases were noted over time for both TMPs and PMPs (Figure 2A,B). TMPs 
peaked at 6 hours (p<0.05; baseline: 708 TMPs/μL plasma [330, 1,336]; 6 hr: 1,301 TMPs/
μL plasma [732, 2,757]; median [IQR]), as was the case for PMPs (p<0.01; baseline: 92 
PMPs/μL plasma [65, 183]; 6 hr: 246 PMPs/μL plasma [157, 765]) with a trend towards 
significance at 3 hours (p=0.09; 3 hr: 232 PMPs/uL plasma [109, 597]). RMP enumeration 
revealed a similar time course with a non-significant increase in peak numbers at 6 hours 
(p=0.09; 3 hr: 190 RMPs/μL plasma [90, 484]; 6 hr: 263 RMPs/μL plasma [133, 718]) 
(Figure 2C). No significant changes were noted for either MMP or EMP subsets.
Coagulation is Activated in Endotoxemia
Plasma TAT levels were significantly elevated at 3 hours compared to baseline (Figure 3B), 
with an almost 15-fold increase (p<0.0001; baseline: 4.5 ± 3.4 μg/mL vs. 3 hr: 65.6 ± 23.9 
μg/mL).
MP-TF Activity on Isolated MPs is Increased in Endotoxemia
As previously described [33], there was a time-dependent increase in MP-TF activity on 
isolated MPs that peaked at 3 hours post LPS infusion (Figure 3A). MP-TF activity 
increased almost 10-fold at 3 hours (p<0.0001) and remained significantly elevated at 6 
hours (p<0.001; [baseline: 0.06 ± 0.05 pg/mL; 3hr: 0.51 ± 0.18 pg/mL; 6hr: 0.47 ± 0.23 
pg/mL; mean ± SD]). However, there was no correlation between MP-TF activity and TAT 
levels at 3 hours (Pearson r=0.206, p=0.50).
MPs in Endotoxemia Display Increased Prothrombinase Activity and Shorten MP-
Dependent Clotting Times
Changes over time in MP prothrombinase activity were similar to those observed with flow 
cytometric analysis of MP numbers (Figure 4), with a significant increase at 3 hours 
(p<0.05; baseline: 1.85 nM PS equivalents [0.89, 2.98]; 3 hr: 5.73 nM PS equivalents [3.87, 
7.04]; median [IQR]) and a peak activity at 6 hours (p<0.0001; 6 hr: 7.74 nM PS equivalents 
[5.11, 11.06]). There were no significant correlations between MP prothrombinase activity 
and TMPs by flow cytometry at any time point. Interestingly, however, there was a strong 
correlation between MP prothrombinase activity and RMPs at 6 hours (Spearman r=0.721; 
p<0.01), with a trend towards moderate correlation at baseline (r=0.475; p=0.056) and at 3 
hours (r=0.471; p=0.059). Additionally, there was a significant correlation between MP 
prothrombinase activity and TAT complexes at 3 hours (r=0.487; p<0.05).
Endotoxin-induced increases in MP procoagulant activity were also observed in plasma in 
the clotting assay. When re-suspended in control PFP, MP-dependent procoagulant activity 
was increased at 3 hours (Figure 5) as evidenced by a significant reduction in clotting time 
compared to baseline (p<0.0001; baseline: 246 ± 46 seconds [s]; 3 hr: 186 ± 39 s; mean ± 
SD).
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MP-Dependent Clotting Occurs in a FXI-Dependent Manner
To evaluate the relative contributions of the extrinsic and intrinsic pathways in MP-mediated 
clot formation, MPs were added to FVII-deficient and FXI-deficient plasma, respectively. 
With both baseline and 3 hour MP samples, there were no significant prolongations of 
clotting times in FVII deficient plasma, indicating that MP-dependent initiation of clot 
formation was not dependent on FVII. In contrast, there was a significant prolongation of 
clotting times observed in FXI deficient plasma at both time points (Figure 5). Using MPs 
obtained from baseline plasma, clotting time increased from 246 ± 46 s (mean ± SD) in 
control PFP to 345 ± 86 s in FXI deficient plasma (p<0.001). Similarly, with MPs obtained 3 
hours after LPS infusion, clotting time increased from 186 ± 39 s in control PFP to 265 ± 63 
s in FXI deficient plasma (p<0.0001).
MPs in Endotoxemia Enhance Thrombin Generation in a FXI-Dependent Manner
Utilizing CAT, MPs generated during endotoxemia shortened the lag time by almost half and 
the time to peak thrombin by one-third compared to baseline MPs, with no significant 
differences in other parameters of thrombin generation (Figure 6A). Using baseline MPs, lag 
time was 37.7 ± 11.4 min (mean ± SD) compared to 22.9 ± 5.7 min using MPs generated 
after 3 hours (p<0.05), and time to peak thrombin decreased from 42.7 ± 11.9 min at 
baseline to 27.8 ± 5.3 min at 3 hours (p<0.05).
When the relative contributions of the intrinsic and extrinsic pathways on MP-initiated 
thrombin generation were examined, observations were consistent with the clotting assay 
results. That is, FXIa inhibition had a significant impact on MP-mediated thrombin 
generation, but no significant changes were observed following TF inhibition (Figure 6B-D). 
Peak thrombin levels were significantly decreased in both baseline and 3-hour MP samples 
with FXIa antibody treatment; for baseline MPs, peak thrombin decreased from 26.6 ± 14.2 
nM (mean ± SD) to 1.3 ± 0.9 nM (p<0.01) with FXIa inhibition, and for 3-hour MPs, peak 
thrombin decreased from 34.7 ± 7.34 nM to 2.5 ± 1.5 nM (p<0.0001). Inhibition of FXIa 
also significantly prolonged lag time and time to peak thrombin, although this was only 
observed with the 3-hour MPs. Lag time increased from 22.9 ± 5.7 min (mean ± SD) to 72.4 
± 42.7 min (p<0.01), and time to peak thrombin increased from 27.8 ± 5.3 min to 85.0 
± 22.6 min (p<0.001). As demonstrated in the representative thrombin generation curve in 
Figure 6A, endogenous thrombin potential (ETP) was also significantly reduced with FXIa 
inhibition, with near complete blunting of thrombin generation at baseline and 3 hours. At 
baseline, ETP decreased from 388.3 nM [206.9, 479.4] (median [IQR]) to 0 nM [0, 10.25] 
(p<0.05), and at 3 hours from 394.8 nM [301.9, 463.0] to 0 nM [0, 20] (p<0.05) with FXIa 
blockade.
No significant difference was noted in thrombin generation profiles with or without PPACK 
treatment of MPs in the endotoxemia subject sample or the ex-vivo LPS stimulated blood 
(Figure 6E–F). In general, MPs were able to promote thrombin generation in all samples. TF 
inhibition had no effect on thrombin generation other than mild prolongation of lag time in 3 
of the samples, whereas inhibition of FXIa again caused nearly complete abrogation of 
thrombin generation. Absence of residual FXIa activity on MPs was also confirmed in 
parallel samples incubated with a chromogenic substrate for FXIa (Figure 6G).
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Discussion
In this study, we sought to characterize circulating MP numbers and phenotype, as well as 
the procoagulant properties of MPs in the human endotoxemia model. Flow cytometry only 
detects the largest MPs, in contrast to functional assays that measure the effects of the entire 
MP population. This discrepancy is worth mentioning, as the smallest MPs may provide a 
procoagulant surface, and in fact the fraction of MPs < 200 nm has been shown to account 
for at least 50% of thrombin generating capacity [37]. We found that MPs induced by 
endotoxin infusion were more procoagulant than baseline (pre-endotoxin) MPs, as 
evidenced by shortened clotting times, shortened lag times and time to peak thrombin with 
CAT, as well as increased MP-associated prothrombinase activity. The latter increased with a 
time course that mirrored increases in MPs detected by flow cytometry with peak values at 6 
hours. Unexpectedly, however, the procoagulant effect of MPs was dependent on FXI, but 
not FVII or TF. Indeed, ETP was almost completely abrogated by an anti-FXIa antibody, 
which was observed both at baseline and at 3 hours. It is notable that others have reported 
similar findings regarding MP-initiated thrombin generation in sepsis, where eight of nine 
patients exhibited strong inhibition of thrombin generation with a monoclonal anti-FXI 
antibody, as compared to only four of nine and two of nine with anti-TF and anti-FXII 
antibodies, respectively [38].
It should be noted that MP-TF activity was not measured in a plasma milieu, and thus 
potentially important natural regulators, such as TFPI, were absent. This limitation 
presumably explains the discrepancy between the MP-TF increase on isolated MPs (Figure 
3A) and the absence of demonstrable TF/FVII(a) dependent activity in plasma-based assays 
(Figures 5 & 6). It may also explain the lack of correlation between MP-TF activity and TAT 
complexes. Others have also shown that increases in a similar MP-TF activity assay in 
cancer patients do not necessarily predict increased microparticle TF-dependent 
procoagulant activity in plasma [39]. Our observations are in contrast to what has been 
reported in a murine model of endotoxemia, where MP-TF activity and TAT levels 
correlated strongly [40]. Although our data indicate that MP-associated TF does not play a 
role in activation of coagulation in human endotoxemia, they do not exclude the possibility 
that other circulating sources of TF – such as that associated with monocytes – may play a 
central role in this regard. This possibility is supported by the fact that TFPI or active site 
inhibited FVIIa largely abrogate coagulation activation in human endotoxemia [41, 42]. 
Thus, although MPs can potentially promote coagulation activation through different 
pathways in endotoxemia (Figure 7), TF-dependent mechanisms do not appear to play a 
significant role in thrombin generation (Table 1).
Recent reports in other clinical settings also support the notion that MPs can promote 
activation of coagulation through the intrinsic pathway. Both PMPs and RMPs generated ex 
vivo were shown to initiate thrombin generation in a FXII-dependent mechanism [43]. In 
sickle cell disease, MP-mediated thrombin generation was reduced 2-fold with an anti-FXI 
antibody but was unaffected by an anti-human TF antibody [44]. The extent of this 
inhibition by the FXI antibody was also significantly correlated with the number of RMPs 
detected by flow cytometry. In a similar study, thrombin generation initiated by RMPs from 
stored red cell units was decreased by approximately 50% in the presence of a FXI 
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inhibitory antibody, whereas no inhibition was noted with an antibody to TF [45]. The 
findings from the latter two studies may be pertinent to our study, in that RMPs were the 
only MP subset to correlate with total PS equivalents at multiple time points, and MP 
prothrombinase activity was the only parameter that correlated with TAT complexes. In 
aggregate, these data suggest a role for RMPs in promoting coagulation via the intrinsic 
pathway.
Enumeration and characterization of MPs was performed using a new generation flow 
cytometer, which allows for detection of smaller MPs [46]. We determined that total MPs 
and PMPs peaked at 6 hours, with a similar trend noted for RMPs. Although the time course 
for these increases differed from that seen with MP-TF activity and TAT complexes [4], they 
were congruous with previously published reports of MP numbers detected by flow 
cytometry in endotoxemia [47].
A potential limitation of our study is the fact that blood samples from endotoxemia subjects 
were not collected in citrate plus CTI to prevent ex vivo activation of the contact pathway. 
Our results, however, support the case that artifactual ex vivo contact activation was not the 
cause for MP-dependent coagulation activation occurring in a FXI-dependent manner. 
Specifically, MPs isolated from endotoxemia subjects were added to pooled, donor PFP 
collected in citrate plus CTI to prevent contact activation. Additionally, treatment of subject 
plasma with PPACK prior to MP isolation did not affect FXI-dependent thrombin 
generation, and these data were also confirmed using MPs generated by ex-vivo LPS 
treatment of whole blood. Further confirmation of the absence of residual ex-vivo generated 
FXIa on MPs was also performed by analyzing samples with a chromogenic substrate for 
FXIa. These data confirm that FXI-dependent thrombin generation was wholly dependent on 
added MPs rather than pre-formed circulating activated contact factors in the substrate or 
test plasmas. Another potential limitation was the fact that we focused exclusively on MPs, 
and did not concurrently measure cell-associated procoagulant activity. However, we [28] 
and others [18] have previously shown that TF mRNA and activity [48] in the mononuclear 
cell fraction increase dramatically in the human endotoxemia model.
In summary, we have found that MPs are increased in human endotoxemia and are 
procoagulant in nature. The largest increases in MP numbers occurred with PMP and RMP 
subsets, both of which peaked at 6 hours post LPS infusion. Our data further demonstrate a 
potentially important role for FXI and the intrinsic pathway in MP-mediated effects on 
coagulation activation in endotoxemia. This effect may not be specific to MPs generated in 
endotoxemia, but rather a property of MPs in general. The mechanism(s) by which MPs 
promote coagulation through the intrinsic pathway, and whether different MP subsets 
activate coagulation through different pathways is not clear. Direct activation of the contact 
pathway, enhancement of thrombin-mediated activation of FXI, or some other unknown 
mechanism may be responsible. Further studies are warranted to evaluate these possibilities.
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Essentials
• The procoagulant effects of microparticles (MPs) on coagulation in endotoxemia 
are not known.
• MPs from endotoxemia volunteers were evaluated for procoagulant activity in a 
plasma milieu.
• MPs from endotoxemia volunteers shortened clotting times and enhanced 
thrombin generation.
• MP procoagulant effects were mediated in a Factor XI dependent manner.
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 6. 
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Figure 7. 
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Table 1
Summary of MP Assays
Assay Environment 
and Contributors to 
MP-Mediated 
Procoagulant Activity
MP-TF Activity MP Prothrombinase Activity MP-dependent Clotting Time MP-mediated Thrombin Generation
Plasma Milieu − − + +
Buffer System + + − −
Phosphatidylserine (PS) + + + +
Tissue Factor (TF) + − − −
Factor XIa (FXIa) − − + +
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